medicalxpress - The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in "magic mushrooms," produced significant improvements in depression compared with a placebo. This is the first publicly funded random…
AI Summary: A publicly funded randomized trial in the UK found that a single dose of psilocybin, delivered in a clinical setting, produced promising improvements for people with treatment-resistant major depressive disorder. The results suggest psychedelic-assisted therapy could be a viable addition to standard care—pending larger trials and careful safety monitoring—challenging old assumptions about one-and-done fixes.
Mid‑stage Parkinson trial failure halts drug development plans / 3 months
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 4 months
FDA backs three psychedelic studies with special commissioner vouchers / 4 months
Cardiology mourns Eugene Braunwald’s death at 96 / 4 months
FDA approves Simtriyo ADHD treatment for children and adults / 29 days
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 4 months
Drug-induced hibernation shows promise to limit stroke brain injury / 2 months
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.